In a recent clonal analysis of tumor samples, the amplification of MYCN occurs in ~ 20 to 30%, ATRX mutations or deletions in ~ 10%, TERT mutations in ~ 10%, and MDM2-CDK mutations in ~ 2% of HR-NB [27]. This evidence concerns the gene MYCN and neuroblastoma.